Kenneth C Murdoch1, Denise Larsen2, Wendy Edey3, Chelsea Arsenault2, Andrew Howell4, Anthony Joyce5, Tricia Sandham2, Janis M Miyasaki6. 1. Department of Educational Psychology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: kcmurdoc@ualberta.ca. 2. Department of Educational Psychology, University of Alberta, Edmonton, Alberta, Canada. 3. Hope Studies Central, University of Alberta, Edmonton, Alberta, Canada. 4. Department of Psychology, MacEwan University, Edmonton, Alberta, Canada. 5. Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada. 6. Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract
INTRODUCTION: Treatment of PD focuses on improving symptoms and quality of life, yet research has not examined interventions aimed at promoting hope in patients. This study examined the effects of a Strength, Hope, and Resources Program for People with PD (SHARP-PWP), based on the principles of positive psychology. METHODS: A mixed method design examined the effects of a randomized, waitlist-controlled trial of SHARP-PWP. 31 PD patients diagnosed in the last 5 years (average age = 66; 13 men, 18 women) participated in a 6-session program. All participants completed self-report measures at pre-treatment, post-treatment, and 6-week follow-up. Data were analyzed using ANOVA. After the program, 15 participants completed a semi-structured interview. Qualitative interview data were analyzed using Interpretive Description. RESULTS: No significant differences in improvement were found between the Immediate and Delayed intervention groups. However, significant effects for time (i.e., pre-treatment to post-treatment) were found for health-related quality of life and well-being in both Immediate and Delayed conditions. Additional quantitative analysis revealed significant improvement in both groups on hope from pre-treatment to follow-up. Qualitative findings revealed that clients identified social, emotional, behavioral and cognitive changes experienced in the group. CONCLUSIONS: Participating in positive psychology research improved health-related quality of life (HrQoL) and mental health and patients identified additional benefits at 6-week follow-up. Our results provide insight about the placebo effect and Hawthorne pre-placebo effects in the context of PD research. The findings can inform trial design and clinical care of patients with PD.
RCT Entities:
INTRODUCTION: Treatment of PD focuses on improving symptoms and quality of life, yet research has not examined interventions aimed at promoting hope in patients. This study examined the effects of a Strength, Hope, and Resources Program for People with PD (SHARP-PWP), based on the principles of positive psychology. METHODS: A mixed method design examined the effects of a randomized, waitlist-controlled trial of SHARP-PWP. 31 PDpatients diagnosed in the last 5 years (average age = 66; 13 men, 18 women) participated in a 6-session program. All participants completed self-report measures at pre-treatment, post-treatment, and 6-week follow-up. Data were analyzed using ANOVA. After the program, 15 participants completed a semi-structured interview. Qualitative interview data were analyzed using Interpretive Description. RESULTS: No significant differences in improvement were found between the Immediate and Delayed intervention groups. However, significant effects for time (i.e., pre-treatment to post-treatment) were found for health-related quality of life and well-being in both Immediate and Delayed conditions. Additional quantitative analysis revealed significant improvement in both groups on hope from pre-treatment to follow-up. Qualitative findings revealed that clients identified social, emotional, behavioral and cognitive changes experienced in the group. CONCLUSIONS: Participating in positive psychology research improved health-related quality of life (HrQoL) and mental health and patients identified additional benefits at 6-week follow-up. Our results provide insight about the placebo effect and Hawthorne pre-placebo effects in the context of PD research. The findings can inform trial design and clinical care of patients with PD.
Authors: Joep van Agteren; Matthew Iasiello; Laura Lo; Jonathan Bartholomaeus; Zoe Kopsaftis; Marissa Carey; Michael Kyrios Journal: Nat Hum Behav Date: 2021-04-19
Authors: Patricia Sánchez-Herrera-Baeza; Roberto Cano-de-la-Cuerda; Edwin Daniel Oña-Simbaña; Domingo Palacios-Ceña; Jorge Pérez-Corrales; Juan Nicolas Cuenca-Zaldivar; Javier Gueita-Rodriguez; Carlos Balaguer-Bernaldo de Quirós; Alberto Jardón-Huete; Alicia Cuesta-Gomez Journal: Sensors (Basel) Date: 2020-04-11 Impact factor: 3.576